Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13779691 | 0.87 | CYP11B1 (0.40) | CHRNB2CHRNA4CTNNB1CYP3A4CYP2D6 | |
| SCHEMBL4205042 | 0.85 | GGPS1 (0.34) | CHRNB2CHRNA4CTNNB1CYP3A4CYP2D6 | |
| SCHEMBL13779692 | 0.72 | CHRNB2 (0.45) | CHRNB2CHRNA4CTNNB1CYP3A4 | |
| SCHEMBL12015774 | 0.71 | CHRNB2 (0.44) | CHRNB2CHRNA4GGPS1 | |
| SCHEMBL4601736 | 0.70 | GGPS1 (0.40) | CHRNB2CHRNA4CTNNB1GGPS1 | |
| SCHEMBL4602800 | 0.68 | CHRNB2 (0.38) | CHRNB2CHRNA4CTNNB1CYP3A4GGPS1 | |
| SCHEMBL9446838 | 0.67 | CHRNB2 (0.40) | CHRNB2CHRNA4GGPS1 | |
| SCHEMBL9446835 | 0.67 | CHEK2 (0.39) | CHRNB2CHRNA4CYP3A4GGPS1 | |
| SCHEMBL11968475 | 0.67 | POLB (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL12384145 | 0.66 | CTNNB1 (0.42) | CTNNB1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1915338-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | CHRNB2 3454/4885CHRNA4 2681/4885CTNNB1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.